Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Atea Pharmaceuticals Inc (AVIR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/18/2025: AVIR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 3.84% | Avg. Invested days 18 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 274.71M USD | Price to earnings Ratio - | 1Y Target Price 7.5 |
Price to earnings Ratio - | 1Y Target Price 7.5 | ||
Volume (30-day avg) 414254 | Beta 0.18 | 52 Weeks Range 2.46 - 4.14 | Updated Date 06/20/2025 |
52 Weeks Range 2.46 - 4.14 | Updated Date 06/20/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.65 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -12.77% | Return on Equity (TTM) -30.47% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -149280880 | Price to Sales(TTM) 1.9 |
Enterprise Value -149280880 | Price to Sales(TTM) 1.9 | ||
Enterprise Value to Revenue 58.97 | Enterprise Value to EBITDA -260.47 | Shares Outstanding 85579504 | Shares Floating 66408817 |
Shares Outstanding 85579504 | Shares Floating 66408817 | ||
Percent Insiders 11.58 | Percent Institutions 68.34 |
Analyst Ratings
Rating 3.33 | Target Price 7.5 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold 1 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Atea Pharmaceuticals Inc
Company Overview
History and Background
Atea Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapies to address unmet medical needs for patients suffering from life-threatening viral diseases. Founded in 2014, the company has focused on developing oral direct-acting antiviral agents for serious viral infections.
Core Business Areas
- Antiviral Drug Development: Atea's primary focus is the development of oral antiviral drugs to combat viral diseases. This includes research, preclinical studies, clinical trials, and potential commercialization.
Leadership and Structure
The leadership team comprises experienced professionals in the pharmaceutical and biotechnology industries. The company's structure includes departments for research and development, clinical operations, regulatory affairs, and finance.
Top Products and Market Share
Key Offerings
- AT-527 (Berenavirsen): AT-527 was Atea's lead product candidate, an oral direct-acting antiviral agent for the treatment of COVID-19. The clinical development program was discontinued. Competitors for potential oral COVID-19 treatments include Pfizer (Paxlovid) and Merck (Molnupiravir).
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly in the antiviral drug development sector, is highly competitive and regulated. Demand for effective antiviral treatments is significant due to the ongoing threat of viral outbreaks and chronic viral infections.
Positioning
Atea Pharmaceuticals aimed to position itself as a leader in oral antiviral drug development. Their competitive advantage was hoped to be developing convenient, orally administered treatments for viral infections.
Total Addressable Market (TAM)
The TAM for antiviral drugs is substantial, estimated to be in the tens of billions of dollars annually. Atea previously positioned itself within the market of COVID-19 oral antivirals. However, the discontinuation of the AT-527 trials impacts this projection
Upturn SWOT Analysis
Strengths
- Experienced management team
- Focus on oral antiviral drug development
- Proprietary technology platform
- Strong IP portfolio (historically)
Weaknesses
- Dependence on a limited number of product candidates
- High cash burn rate
- Significant clinical and regulatory risks
- Reliance on partnerships for funding and development
- Lack of marketed products
Opportunities
- Potential for breakthrough antiviral therapies
- Partnerships with larger pharmaceutical companies
- Expansion into new antiviral targets
- Government funding and support for antiviral research
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Generic erosion of existing antiviral drugs
- Changes in the epidemiology of viral diseases
Competitors and Market Share
Key Competitors
- PFE
- MRK
- GILD
Competitive Landscape
Atea faces intense competition from established pharmaceutical companies with greater resources and experience in drug development and commercialization.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been focused on advancing product candidates through clinical trials.
Future Projections: Future growth is highly uncertain and dependent on the success of new clinical trials or new partnerships.
Recent Initiatives: Recent initiatives focus on the company's ongoing research efforts.
Summary
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company facing significant challenges. The discontinuation of the AT-527 clinical trials significantly impacted the company's prospects. The company's future success depends on the success of its other research and its ability to secure partnerships and funding. Further research and development is crucial to see any type of return.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Third-party market research
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data is based on available information and may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Atea Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2020-10-30 | Founder, Chairman, CEO & President Dr. Jean-Pierre Sommadossi Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 56 | Website https://ateapharma.com |
Full time employees 56 | Website https://ateapharma.com | ||
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.